1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)

• DOI: 10.1016/j.annonc.2023.09.1113
• Publication Date: 2023-10-20T11:59:17Z
• Authors: M.H. Voss; B. Garmezy; S.H. Kim; J.P. Maroto Rey; A.B. Mansinho; A. Rodriguez-Vida; J. Oliveira; M. van Dongen; L. Medina Rodríguez; S. Negrier; B. Tran; B.A. Carneiro; E. Castanon Alvarez; S.Y. Rha; Y. Wang; S.D. Gainer; Z. Tang; I. Achour; J.M. Asare; L. Albiges
• Keywords: CTLA-4